| Ytd | -22.82% | |
| 1y | -4.96% |
| Open | 1.15 | Prev Close | 1.16 | Low | 1.15 | High | 1.15 | Mkt Cap | 19.17M |
| Vol | 46.02K | Avg Vol | 58.93K | EPS | -0.61 | P/E | -1.89 | Forward P/E | -2.34 |
| Beta | 1.49 | Short Ratio | 1.55 | Inst. Own | 22.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.31 | 200-d Avg | 1.41 | 1yr Est | 19.00 |
MRKR News
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a
MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses,
After reaching an important support level, MARKER THERAPEUTICS, INC. (MRKR) could be a good stock pi
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may p
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractor
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T c
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
Marker Therapeutics, Inc. MRKR on Tuesday provided an update on the progress and clinical observatio
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 6
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stag
Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced a
Gainers Clovis Oncology, Inc. (NASDAQ: CLVS) shares climbed 47.7% to close at $7.86 on Friday af
Gainers Clovis Oncology, Inc. (NASDAQ: CLVS) shares jumped 44.8% to $7.70 after the company anno
On Tuesday, 596 companies set new 52-week highs.